title: [Sequential inhibition of angiogenesis in metastatic colorectal cancer: activity and efficacy of aflibercept].
abstract: We report a case of a young adult affected by an adenocarcinoma of the ascending colon with synchronous, unresectable liver metastases, diagnosed on April, 2011. The patient received a first-line of bio-chemotherapy with standard folfox regimen in association with bevacizumab. Deriving from which a good partial remission of the disease with its conversion to operability; so he underwent a right hemicolectomy with liver metastasectomy. Eleven months after radical surgery, the patient experimented an intrahepatic progression of the tumour, so he started a second-line therapy with FOLFIRI regimen plus aflibercept. Six months later than the beginning of the treatment he underwent a second liver metastasectomy. He subsequently received further twelve months of the same regimen. The patient is still alive forty-six months later than the diagnosis of the disease, expressing a good performance status and he's on fourth-line chemotherapy due to a relapse of its tumour.
authors.forename: Concetta
authors.initials: C
authors.lastname: Martines
authors.forename: Stefano
authors.initials: S
authors.lastname: Cordio
authors.forename: Roberto
authors.initials: R
authors.lastname: Bordonaro
mesh_terms: D000328:Adult; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor